FDA grants Emergency Use Authorization to Quest Diagnostics for Zika Test

| Printer friendly version

According to Medical Device Daily, the US Food and Drug Administration (FDA) has authorized the emergency use of a diagnostic molecular test developed by Quest Diagnostics subsidiary, Focus Diagnostics Inc., in response to growing concerns over the recent Zika virus outbreak. According to the report, this is the first test from a commercial lab to receive emergency use authorization to test U.S. patients for the Zika virus. It could potentially significantly broaden the access of U.S. physicians to diagnose the virus, as previously Zika tests were limited to qualified CDC-designed laboratories. As a result, more patients can be screened and individuals with the disease can be identified earlier.

According to the FDA, Quest’s Zika Virus RNA Qualitative Real-Time RT-PCR test is intended for the qualitative detection of Zika virus RNA in human serum approximately 4-7 days following onset of symptoms, which include fever, joint pain, rash, or conjunctivitis. In particular, the CDC recommends testing for individuals with symptoms suggestive of Zika infection who have traveled within the last two weeks to an area with ongoing transmission, asymptomatic pregnant women with a history of residence in or travel to areas of active Zika infection, asymptomatic pregnant women whose male sexual partners have traveled to or lived in an area of active Zika infection, and infants born to mothers who live in or traveled to areas with Zika virus transmission during their pregnancy – including both molecular and serologic testing of infants who are being evaluated for evidence of a congenital Zika virus infection.


Show Wang
Show Wang is an associate in our Orange County office. In 2009, Mr. Wang graduated with a degree in Biomedical Engineering from Duke University, where he researched and built low-cost wireless ECG machines. After graduation, Mr. Wang worked at a hedge fund before helping a biomedical startup model the thermal profiles of surgically-implantable cooling chips. While attending law school, Mr. Wang spent some time at the USPTO as an examiner extern. Mr. Wang graduated from New York University School of Law in 2014. Mr. Wang was a summer associate with the firm in 2013, and joined the firm as an associate in 2014.
Click here to read full bio
View all posts published by Show Wang »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.